CDC Ph President Dr. Benigno Agbayani, Jr. issues a response to the Philippine FDA’s memo regarding the use of Veterinary Ivermectin:
�A Response to the Philippine FDA Memo on Ivermectin Use
From Dr. Bienvenido Agbayani, Jr.
�Concerned Doctors and Citizens of the Philippines (CDC Ph)�
Ivermectin is a drug under the Essential Medicines List of both the Philippine FDA and the World Health Organization (WHO). Just like all responsible Filipino physicians, the doctors of CDC Ph neither prescribe nor encourage the use of veterinary grade drugs for humans. Instead, we would like to emphasize that Ivermectin has had over a billion doses prescribed worldwide and more than 40 years of high safety profile use on humans. ��
Ivermectin has accumulated a very strong body of published scientific evidence over the last few months. More recently, it was endorsed to the WHO by the British Ivermectin Recommendation Development (BIRD), an international team of independent scientists and professional researchers.
The BIRD states this conclusion in their meta-analysis:��
“The British Ivermectin Recommendation Development panel recommends ivermectin for the prevention and treatment of covid-19 to reduce morbidity and mortality associated with covid-19 infection and to prevent covid-19 infection among those at higher risk.”�� It is our opinion at Concerned Doctors and Citizens of the Philippines that a life-saving drug like Ivermectin should be given all the urgent support and attention it needs to lift the Filipino people out of this period of historic widespread fear and suffering.
For reference, here is the summary of the BIRD recommendation:
SUMMARY OF EFFECTS
The evidence from meta-analyses show that ivermectin treatment may reduce the risk of death among people with covid-19 by an average of 68% (27% to 86%). Analysis also suggests that, in contexts where the death rate among hospitalized patients is high (around 9.1%), the number needed to treat (NNT) to prevent one death may be around 16 patients (95% CI 13 to 41). The evidence also suggests that it may lead to fewer patients deteriorating if they receive ivermectin compared with them not getting ivermectin. Severe adverse events were infrequent suggesting there may be little or no difference in these events with ivermectin use.�
With regard to prophylaxis among those with high exposure, the evidence shows that prevention with ivermectin may reduce the risk of getting infected with covid-19 infection by an average of 86% (79% to 91%). The NNT to prevent one covid-19 infection among those with high exposure may be around 4 (95% CI 4 to 4). No severe adverse events occurred in the two studies reporting this outcome.��
Dr Iggy Agbayani